Regeneron Class Action: Join by March 10, 2025 – Contact Levi & Korsinsky

Investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have until March 10, 2025, to join a class action lawsuit alleging securities fraud against the biotechnology giant. The lawsuit, spearheaded by the law firm Levi & Korsinsky, claims that Regeneron misled investors regarding pricing practices related to its blockbuster drug, Eylea, potentially violating federal regulations.

Allegations Against Regeneron

According to court filings, Regeneron allegedly provided credit card fee subsidies to distributors, ensuring that customers were not charged extra fees when purchasing Eylea. By doing so, the company effectively reduced the drug’s actual price while not reporting these payments as price concessions. This practice, if proven, could mean that Regeneron misrepresented the Average Sales Price (ASP) of Eylea to federal agencies, potentially violating the False Claims Act (Department of Justice).

The lawsuit covers investors who purchased Regeneron stock between November 2, 2023, and October 30, 2024. It argues that by failing to disclose these details, Regeneron may have artificially inflated its stock price, leading to financial losses for shareholders.

Potential Legal Violations

The core of the case revolves around whether Regeneron’s pricing strategy misled investors and federal regulators. The Securities and Exchange Commission (SEC) (SEC.gov) mandates that publicly traded companies provide accurate and complete financial information. If Regeneron knowingly misrepresented its ASP reporting, it could face regulatory penalties and restitution claims from investors.

Additionally, the lawsuit suggests a possible breach of the False Claims Act, which prohibits false statements made to obtain government funds. If proven, Regeneron could be held liable for damages, including penalties under federal healthcare laws (Centers for Medicare & Medicaid Services).

Impact on Investors

Shareholders who invested in Regeneron during the affected period may have suffered financial losses due to the company’s alleged misrepresentation. If the lawsuit succeeds, investors may be eligible for compensation based on stock price fluctuations linked to the alleged misinformation.

Those interested in joining the lawsuit must act before March 10, 2025. By joining as a lead plaintiff, an investor can take a more active role in directing the litigation. The lead plaintiff represents the entire class and plays a critical role in settlement negotiations and trial proceedings.

How to Join the Class Action Lawsuit?

Investors seeking to participate can contact Levi & Korsinsky through the following channels:

• Website: zlk.com
• Email: [email protected]
• Phone: (212) 363-7500

Before joining, investors are encouraged to consult legal professionals or review relevant guidelines from the U.S. Securities and Exchange Commission (SEC Investor Bulletin) on class action participation.

Regeneron’s Response

As of now, Regeneron has not publicly commented on the lawsuit. However, the company could face increasing scrutiny from investors and regulatory bodies if the allegations hold merit. If found guilty of securities fraud, Regeneron could be subject to fines, settlements, and long-term reputational damage.

Conclusion

With the March 10, 2025 deadline approaching, Regeneron investors should carefully evaluate their legal options. This case could have significant financial implications, not only for the company but also for shareholders who may have been misled. Investors are advised to stay informed, review their investment history, and consider joining the class action if they qualify.

For the latest updates on the case and other investor-related legal matters, visit SEC.gov or consult legal professionals specializing in securities litigation.

This article has been carefully fact-checked by our editorial team to ensure accuracy and eliminate any misleading information. We are committed to maintaining the highest standards of integrity in our content.